These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 19951380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
    Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    Intervirology; 2009; 52(4):179-88. PubMed ID: 19546575
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P.
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [Abstract] [Full Text] [Related]

  • 5. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.
    Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A.
    Gastroenterology; 2006 May; 130(6):1661-9. PubMed ID: 16697730
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.
    Masarone M, La Mura V, Bruno S, Gaeta GB, Vecchione R, Carrino F, Moschella F, Torella R, Persico M.
    J Viral Hepat; 2007 Oct; 14(10):714-20. PubMed ID: 17875006
    [Abstract] [Full Text] [Related]

  • 10. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
    Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG.
    J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
    [Abstract] [Full Text] [Related]

  • 11. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
    [Abstract] [Full Text] [Related]

  • 12. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.
    Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.
    J Med Virol; 2010 Jan; 82(1):41-8. PubMed ID: 19950230
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes.
    Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Yoshida N, Yasui K, Itoh Y, Okanoue T, Yoshikawa T.
    J Gastroenterol Hepatol; 2011 May; 26(5):836-42. PubMed ID: 21054524
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [Abstract] [Full Text] [Related]

  • 17. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.
    Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ.
    Dig Liver Dis; 2007 Oct; 39(10):936-42. PubMed ID: 17720637
    [Abstract] [Full Text] [Related]

  • 18. Hepatic steatosis in Iranian patients with chronic hepatitis C.
    Minakari M, Sameni FK, Shalmani HM, Molaee M, Zali MR.
    Med Princ Pract; 2008 Oct; 17(2):126-30. PubMed ID: 18287796
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response.
    Kumar D, Farrell GC, Fung C, George J.
    Hepatology; 2002 Nov; 36(5):1266-72. PubMed ID: 12395339
    [Abstract] [Full Text] [Related]

  • 20. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I, Aponte N, Fernández-Carbia A, Rodríguez-Perez F, Toro DH.
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.